Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study

BACKGROUND: Apatinib is established to be the standard of care as third-line therapy for patients with previously treated advanced gastric cancer (GC). Programmed cell death protein 1 (PD-1) blockades also exhibited promising efficacy and safety for patients with treatment-refractory advanced GC. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li-Hua, Chen, Wen-Chao, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076296/
https://www.ncbi.nlm.nih.gov/pubmed/35531474
http://dx.doi.org/10.1155/2022/4322404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076296/
https://www.ncbi.nlm.nih.gov/pubmed/35531474
http://dx.doi.org/10.1155/2022/4322404

Ejemplares similares